Sector: Health Care
Director information for NKARTA INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Ali Behbahani | Chair | [] | [] | 2026 | |
| Ali Behbahani, M.D., M.B.A. | Chairman | 50 | ["Partner and Co-Head of the healthcare team at New Enterprise Associates, Inc.","Board member of multiple publicly held companies in the biopharmaceutical industry","Consultant in business development at The Medicines Company","Venture Associate at Morgan Stanley","Healthcare Investment Banking Analyst at Lehman Brothers","B.S. in biomedical engineering, electrical engineering, and chemistry from Duke University","M.D. from the University of Pennsylvania School of Medicine","M.B.A. from the Wharton School of the University of Pennsylvania"] | [] | 2026 |
| Angela Thedinga | Director | 44 | ["Founder and principal consultant for Agenvia, LLC","Former Chief Technology Officer of Adverum Biotechnologies, Inc.","Former VP, Program Management and Strategy at Adverum Biotechnologies, Inc.","Former VP, Program Management and Chief of Staff at AveXis, Inc.","Experience in manufacturing strategy roles at AveXis, Inc., Novartis Vaccines and Diagnostics, and Abbott Laboratories","B.S. in chemical engineering from the University of Wisconsin - Madison","M.S. in chemical engineering from the Massachusetts Institute of Technology","M.B.A. from the MIT Sloan School of Management","M.P.H. from the University of North Carolina Chapel Hill"] | [] | 2026 |
| George Vratsanos, M.D., FACR | President and Chief Executive Officer | 62 | ["Expertise in immunology","Leadership and management experience"] | [] | 2026 |
| Leone Patterson, M.B.A. | Director | 63 | ["Executive Vice President and Chief Business and Financial Officer of Zymeworks Inc.","Chief Financial and Business Officer of Tenaya Therapeutics, Inc.","Chief Financial Officer of Adverum Biotechnologies, Inc.","Chief Executive Officer of Adverum Biotechnologies, Inc.","Director of Adverum Biotechnologies, Inc.","President of Adverum Biotechnologies, Inc.","Senior positions at Diadexus, Inc., Transcept Pharmaceuticals, Inc., NetApp, Inc., Exelixis, Inc., Novartis AG, Chiron, and KPMG","B.S. in business administration and accounting from Chapman University","Executive M.B.A. from St. Mary’s College","Certified Public Accountant (inactive status)","Over 20 years of experience in the biotechnology industry"] | [] | 2026 |
| Michael Dybbs | [] | [] | 2026 | ||
| Michael Dybbs, Ph.D. | Director | 51 | ["Partner at Samsara BioCapital","Partner at New Leaf Venture Partners, L.L.C.","Principal at Boston Consulting Group","Board member at Sutro Biopharma, Inc.","Board member at Kalaris Therapeutics, Inc.","Experience in life sciences industry","Experience in venture capital industry","Leadership and management experience"] | [] | 2026 |
| Nadir Mahmood, Ph.D. | President | ["Formerly served as Chief Executive Officer at Rezo Therapeutics","Chief Financial and Business Officer at the company","Chief Business Officer from September 2019 to October 2020","Senior Vice President, Corporate Development from May 2018 to September 2019","Held positions at Second Genome, Inc. between March 2012 and April 2018","Equity Research Fellow in Global Investment Research at Goldman Sachs Inc.","Postdoctoral research at the Scripps Research Institute","Staff Scientist at Kythera Biopharmaceuticals"] | ["Chair of the Board of Directors of California Life Sciences"] | 2026 | |
| Paul J. Hastings | Chief Executive Officer | 66 | ["Extensive experience in the pharmaceutical and biotechnology industries","Former President and Chief Executive Officer of OncoMed Pharmaceuticals, Inc.","Former President and Chief Executive Officer of QLT, Inc.","Former President and Chief Executive Officer of Axys Pharmaceuticals, Inc.","Former chair of the board of directors of Pacira Biosciences, Inc.","Former chair of the board of directors of Proteolix, Inc.","Chair of the Biotechnology Innovation Organization from 2021 to 2023"] | ["Executive Committee","Emerging Companies Section","Health Section Governing Board"] | 2026 |
| Shawn Rose, M.D., Ph.D. | Chief Medical Officer and Head of Research and Development | ["Formerly served as President and Owner of an independent research and development advisory LLC","Chief Development Officer, Immunology at Vividion Therapeutics","Senior Vice President and Head of the Clinical Development Organization at Magenta Therapeutics","Led autoimmunity clinical development at Annexon Biosciences","Held positions of increasing responsibility at Johnson & Johnson","Director within Immunoscience at Bristol-Myers Squibb","Attending physician and researcher at the NIH Clinical Center","Completed internal medicine residency and clinical and research fellowship in Rheumatology"] | [] | 2026 | |
| Simeon George, M.D., M.B.A. | Chief Executive Officer and Managing Partner | 49 | ["Chief Executive Officer and Managing Partner of SR One Capital Management, LP","Former Chief Executive Officer and President of S.R. One, Limited","Consultant at Bain & Company","Investment banker at Goldman Sachs and Merrill Lynch","Experience on the boards of several biotech and health-related companies"] | [] | 2026 |
| Zachary Scheiner | [] | [] | 2026 | ||
| Zachary Scheiner, Ph.D. | Director | 49 | ["Experience in the life sciences industry","Investing experience"] | [] | 2026 |
